Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - letrozole 2.5mg;   - film coated tablet - 2.5 mg - active: letrozole 2.5mg   excipient: colloidal silicon dioxide hypromellose as 0.087 mg pigment suspension white + 0.087 mg pigment suspension yellow + 1.663 mg additional iron oxide yellow lactose monohydrate macrogols magnesium stearate maize starch microcrystalline cellulose purified talc sodium starch glycolate titanium dioxide - adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer extended adjuvant treatment of invasive early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy for five years. first-line treatment in postmenopausal women with advanced breast cancer advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - gemcitabine hydrochloride 11.39 mg/ml equivalent to gemcitabine 10 mg/ml;   - concentrate for injection - 10 mg/ml - active: gemcitabine hydrochloride 11.39 mg/ml equivalent to gemcitabine 10 mg/ml   excipient: sodium acetate trihydrate sodium hydroxide water for injection - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 6 miu/ml;   - solution for injection - 3miu/0.5ml - active: interferon alfa-2a 6 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 12 miu/ml;   - solution for injection - 6miu/0.5ml - active: interferon alfa-2a 12 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - interferon alfa-2a 18 miu/ml;   - solution for injection - 9miu/0.5ml - active: interferon alfa-2a 18 miu/ml   excipient: ammonium acetate benzyl alcohol glacial acetic acid polysorbate 80 sodium chloride sodium hydroxide water for injection - roferon-a is indicated for the treatment of basal cell carcinoma, carcinoid syndrome, chronic lymphocytic leukaemia (early stage), chronic myelogenous leukaemia, , condylomata acuminata, cutaneous t cell lymphoma (mycosis fungoides and sezary syndrome), essential thrombocythaemia, hairy cell leukaemia, kaposi's sarcoma associated with aids, malignant melanoma, multiple myeloma, non-hodgkin's lymphoma (low and intermediate grade), renal cell carcinoma (recurrent or metastatic).

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

viatris limited - letrozole 2.5mg; letrozole 2.5mg - film coated tablet - 2.5 mg - active: letrozole 2.5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry yellow 40l92586 purified water sodium starch glycolate active: letrozole 2.5mg excipient: colloidal silicon dioxide opadry ii yellow 40l38238 lactose monohydrate magnesium stearate maize starch microcrystalline cellulose purified water sodium starch glycolate - adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. · extended adjuvant treatment of early breast cancer in post menopausal women who have received greater than or equal to 4.5 and less than or equal to 6.0 years prior standard adjuvant tamoxifen therapy. · first-line treatment in postmenopausal women with advanced breast cancer. · treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antioestrogens.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

viatris limited - letrozole 2.5mg - film coated tablet - 2.5 mg - active: letrozole 2.5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch microcrystalline cellulose opadry yellow 40l38238 purified water sodium starch glycolate - adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. · extended adjuvant treatment of early breast cancer in post menopausal women who have received greater than or equal to 4.5 and less than or equal to 6.0 years prior standard adjuvant tamoxifen therapy. · first-line treatment in postmenopausal women with advanced breast cancer. · treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antioestrogens.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - fluorouracil 5%{relative};  ;   - topical cream - 5% w/w - active: fluorouracil 5%{relative}     excipient: methyl hydroxybenzoate polysorbate 60 propyl hydroxybenzoate propylene glycol purified water stearyl alcohol white soft paraffin - dp-fluorouracil is used for the topical treatment of superficial pre-malignant and malignant skin lesions; keratoses including senile, actinic and arsenical forms, keratoa canthoma; bowen's disease; superficial basal-cell carcinoma.

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

marigny nz ltd - piroctone olamine 0.25% - scalp lotion - 0.25 % - active: piroctone olamine 0.25%

Нови Зеланд - Енглески - Medsafe (Medicines Safety Authority)

marigny nz ltd - piroctone olamine 0.45%{relative} - shampoo - 0.45% w/w - active: piroctone olamine 0.45%{relative} excipient: dibasic sodium phosphate ethylcellulose glyceryl distearate methyl hydroxybenzoate povidone surfactants